The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. - Wikidata - awgldk - TriplyDB

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

http://www.wikidata.org/entity/Q33825555

about

Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancer Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-κB and TNFα to Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells.TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer.Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis.MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

P2860

Q27318699-17C5D82F-46E1-4521-ADEC-BD3B9A2A6B5B Q28083164-E37A1A5B-53CC-4407-A7EC-1D64E1D53340 Q34968735-AE937EC4-69C6-43A8-96A2-732A4B4AB8BA Q36842192-155CEB8E-3FC3-4834-97C8-D238BFE95901 Q37396607-0F58EEF4-443F-448C-BA14-EAAD4F2C7ED9 Q37727225-F3FCAA46-A327-4523-B740-F8FB1889020E Q38747875-17FA1F6F-89E4-4DFB-A5E5-15FCBB42509A Q38784593-DCC16582-2785-4348-9B85-4FBF84A80062 Q38832323-913D5758-A18D-4E00-9362-46103D09D57A Q47699244-7ED197CD-77A6-4A02-8598-68F58DB3CA2D Q47995197-D51D2859-50B8-42C8-A176-AB672C6E7E93 Q52608528-3C3222CF-896F-4420-B139-30FEEA229A1B Q52645842-4CF28761-C91A-403A-8FB8-E506F1A8F527 Q52675313-11E524F3-1CA6-4771-98F7-2334B5D5C25A

P2860

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

http://www.wikidata.org/entity/Q33825555

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@ast

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@en

type

label

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@ast

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@en

prefLabel

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@ast

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@en

P1433

Q33825555-DEE69D7F-605A-4D26-A672-A58A0DDBDD89

P1476

Q33825555-95859490-4D0F-433B-B3D6-9666E78E164D

P2093

Q33825555-00B4E8A5-ACE7-4CD4-B6AF-BF8973764CE2

Q33825555-194548BE-4BA8-4C47-A4DB-A5974663F259

Q33825555-325E1AFA-3DED-45C0-A604-C3A24875C50A

Q33825555-3D504059-53F3-4E68-A82D-8117E6704EE5

Q33825555-4494DC80-DCFF-4C8E-A951-ED438D74059B

Q33825555-4D5F9F93-22A5-4BD7-865F-CC5F8028E9A7

Q33825555-51A09740-BFCA-43F0-908A-E4635145BC36

Q33825555-53B30EC8-62A7-418E-88F4-2CF016B74646

Q33825555-62CE594F-77DE-4175-A48D-4F53D79CF3D0

Q33825555-661C1540-D44C-457A-B35B-39455F1046C9

P2860

Q33825555-04FD4FCE-0826-4357-B404-DB8A8D600AF1

Q33825555-1C230287-A906-4855-8DC8-582395D28C62

Q33825555-1F558E91-403A-48C1-B642-B537A952C23D

Q33825555-1F5F0699-EF88-4F82-A38C-9DC2B77A282C

Q33825555-20D8DF9D-9216-44B6-BECE-05D4A1A811E8

Q33825555-2A10ECCB-C88C-40AA-A5E8-043661FE1F74

Q33825555-2F1B2FD0-268C-4E53-A014-08469C64AB41

Q33825555-34C4AED8-6DA3-46F0-95DA-744BB9A64D48

Q33825555-3DC54122-C616-4B28-883D-EF25574823CA

Q33825555-49180609-62E3-4CD2-8AA6-1BDC1BB57E36

P304

Q33825555-4570EF6C-B8E0-4E51-9E8E-5A9D593A72B1

P31

Q33825555-5CC7C3E6-6B0E-4230-87F7-A63BA3CAA022

P356

Q33825555-1482DC5F-47CB-40F0-AB22-D2E518CA357F

P407

Q33825555-2636F9BA-0BBC-4DDA-854A-61D16C7F52D3

P433

Q33825555-76E4BF05-BB69-4CD7-930B-3B60BD584228

P478

Q33825555-F7FEE103-5E47-473E-A2DE-143761A20485

P50

Q33825555-04219FA4-BEFB-4C77-BDB7-0257ADDE86E7

Q33825555-2A0F0FAD-397E-4376-989C-FF885F8F5A59

Q33825555-2B1572C2-8855-4660-A77B-B2BBEF723222

Q33825555-463FCD92-11AC-4039-904C-FEF5C05369D4

Q33825555-59D0E179-A031-4D00-B4DC-A683CD2FDEF8

Q33825555-7F33B9F6-CE04-456E-9C2B-9278F2919786

Q33825555-8318B1AA-9E7F-4D9E-92A1-B5CB81BDB246

Q33825555-95A20E31-0ED4-4489-BC62-B6010674A1C5

Q33825555-9D3342A0-87DC-4B73-9715-9603C20726E8

Q33825555-A6EB5CD8-252D-44BB-BCDF-48BAD2F03B10

P577

Q33825555-647C7C73-AB0A-4F4A-B185-DEFEC5E8183E

P5875

Q33825555-C2F3610D-4E9C-4D49-8512-C3B638E9438F

P698

Q33825555-1E043770-8A3D-449E-9378-81F0B9065F91

P932

Q33825555-BE8B0A5E-86B8-461D-9B5D-D1604AD35B7C

P356

JOURNAL.PONE.0100816

P1433

P1476

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

@en

P2093

Brian Flood

http://www.w3.org/2001/XMLSchema#string

Bryan Hennessy

http://www.w3.org/2001/XMLSchema#string

Charles J d'Adhemar

http://www.w3.org/2001/XMLSchema#string

Ciara Murphy

http://www.w3.org/2001/XMLSchema#string

Dearbhaile O'Donnell

http://www.w3.org/2001/XMLSchema#string

Jacqui Barry-O'Crowley

http://www.w3.org/2001/XMLSchema#string

Kathryn Haley

http://www.w3.org/2001/XMLSchema#string

Katie M Costello

http://www.w3.org/2001/XMLSchema#string

Ken O'Byrne

http://www.w3.org/2001/XMLSchema#string

Niamh Kernan

http://www.w3.org/2001/XMLSchema#string

P2860

NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

MicroRNAs: genomics, biogenesis, mechanism, and function

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein

Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification

Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21

Negative regulation of toll-like receptor-mediated immune responses

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.

Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients.

P304

e100816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0100816

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Luke A. J. O'Neill

Stephen P. Finn

Stephen R. Pennington

Brendan Ffrench

Michael Gallagher

P577

2014-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263514566

http://www.w3.org/2001/XMLSchema#string

P698

24977712

http://www.w3.org/2001/XMLSchema#string

P932

4076208

http://www.w3.org/2001/XMLSchema#string